Drug Profile
Research programme: antibody therapeutics - Adimab/Gilead
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Adimab; Gilead Sciences
- Developer Adimab
- Class Antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Immunological disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Immunological-disorders in USA (Parenteral)
- 08 Jul 2016 Gilead Sciences in-licenses OmniRat®, OmniMouse® and OmniFlic® platforms from Ligand Pharmaceuticals to develop antibodies
- 23 Apr 2012 Early research in Immunological disorders in USA (Parenteral)